Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa TdT-3 in relapsed or refractory TdT-positive acute leukemia or lymphoblastic lymphoma
2024-519320-24-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Jul 2026
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TDT-3 in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by Oslo University Hospital. Primary endpoints: Dose-limiting toxicities, Safety profile and 2 more. Planned start Jul 2026; status: authorised.
02
Drugs
TDT-3
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on 2024-519320-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519320-24-00.